- Home
- ASAN vs ARQT Comparison
ASAN vs ARQT Comparison
Compare ASAN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASAN | ARQT |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ASAN | ARQT |
|---|---|---|
| Price | $6.09 | $24.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | $12.46 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 5.9M | 1.1M |
| Earning Date | 06-02-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.93 | ★ 88.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $790,806,000.00 | $376,072,000.00 |
| Revenue This Year | $10.19 | $34.46 |
| Revenue Next Year | $7.91 | $29.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 9.25 | ★ 91.34 |
| 52 Week Low | $5.38 | $12.42 |
| 52 Week High | $19.00 | $31.77 |
Technical Indicators
Market Signals| Indicator | ASAN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 53.64 |
| Support Level | $5.87 | $22.56 |
| Resistance Level | $6.67 | $25.03 |
| Average True Range (ATR) | 0.39 | 0.96 |
| MACD | 0.03 | 0.31 |
| Stochastic Oscillator | 52.33 | 76.90 |
Price Performance
Historical ComparisonAbout ASAN Asana Inc.
Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.